Ultrasound Blood-Brain Barrier Opening and Aducanumab in Alzheimer's Disease.

IF 78.5 1区医学 Q1 MEDICINE, GENERAL & INTERNAL

New England Journal of Medicine Pub Date : 2024-01-04 DOI:10.1056/NEJMoa2308719

Ali R Rezai, Pierre-Francois D'Haese, Victor Finomore, Jeffrey Carpenter, Manish Ranjan, Kirk Wilhelmsen, Rashi I Mehta, Peng Wang, Umer Najib, Camila Vieira Ligo Teixeira, Tasneem Arsiwala, Abdul Tarabishy, Padmashree Tirumalai, Daniel O Claassen, Sally Hodder, Marc W Haut

{"title":"Ultrasound Blood-Brain Barrier Opening and Aducanumab in Alzheimer's Disease.","authors":"Ali R Rezai, Pierre-Francois D'Haese, Victor Finomore, Jeffrey Carpenter, Manish Ranjan, Kirk Wilhelmsen, Rashi I Mehta, Peng Wang, Umer Najib, Camila Vieira Ligo Teixeira, Tasneem Arsiwala, Abdul Tarabishy, Padmashree Tirumalai, Daniel O Claassen, Sally Hodder, Marc W Haut","doi":"10.1056/NEJMoa2308719","DOIUrl":null,"url":null,"abstract":"<p><p>Antiamyloid antibodies have been used to reduce cerebral amyloid-beta (Aβ) load in patients with Alzheimer's disease. We applied focused ultrasound with each of six monthly aducanumab infusions to temporarily open the blood-brain barrier with the goal of enhancing amyloid removal in selected brain regions in three participants over a period of 6 months. The reduction in the level of Aβ was numerically greater in regions treated with focused ultrasound than in the homologous regions in the contralateral hemisphere that were not treated with focused ultrasound, as measured by fluorine-18 florbetaben positron-emission tomography. Cognitive tests and safety evaluations were conducted over a period of 30 to 180 days after treatment. (Funded by the Harry T. Mangurian, Jr. Foundation and the West Virginia University Rockefeller Neuroscience Institute.).</p>","PeriodicalId":54725,"journal":{"name":"New England Journal of Medicine","volume":"390 1","pages":"55-62"},"PeriodicalIF":78.5000,"publicationDate":"2024-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"New England Journal of Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1056/NEJMoa2308719","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Antiamyloid antibodies have been used to reduce cerebral amyloid-beta (Aβ) load in patients with Alzheimer's disease. We applied focused ultrasound with each of six monthly aducanumab infusions to temporarily open the blood-brain barrier with the goal of enhancing amyloid removal in selected brain regions in three participants over a period of 6 months. The reduction in the level of Aβ was numerically greater in regions treated with focused ultrasound than in the homologous regions in the contralateral hemisphere that were not treated with focused ultrasound, as measured by fluorine-18 florbetaben positron-emission tomography. Cognitive tests and safety evaluations were conducted over a period of 30 to 180 days after treatment. (Funded by the Harry T. Mangurian, Jr. Foundation and the West Virginia University Rockefeller Neuroscience Institute.).

查看原文本刊更多论文

超声波血脑屏障开放与阿杜卡单抗在阿尔茨海默病中的应用

抗淀粉样蛋白抗体已被用于减少阿尔茨海默病患者的脑淀粉样蛋白-β（Aβ）负荷。我们在每月六次输注阿杜单抗时使用聚焦超声，暂时打开血脑屏障，目的是在 6 个月的时间内增强三位参与者选定脑区的淀粉样蛋白清除能力。根据氟-18氟贝他苯正电子发射断层扫描的测量结果，接受聚焦超声治疗的区域的Aβ水平下降幅度要高于未接受聚焦超声治疗的对侧半球的同源区域。认知测试和安全性评估在治疗后 30 到 180 天内进行。(由 Harry T. Mangurian, Jr.基金会和西弗吉尼亚大学洛克菲勒神经科学研究所资助）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

New England Journal of Medicine 医学-医学：内科

CiteScore

145.40

自引率

0.60%

发文量

1839

审稿时长

1 months

期刊介绍： The New England Journal of Medicine (NEJM) stands as the foremost medical journal and website worldwide. With an impressive history spanning over two centuries, NEJM boasts a consistent publication of superb, peer-reviewed research and engaging clinical content. Our primary objective revolves around delivering high-caliber information and findings at the juncture of biomedical science and clinical practice. We strive to present this knowledge in formats that are not only comprehensible but also hold practical value, effectively influencing healthcare practices and ultimately enhancing patient outcomes.